New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
07:44 EDTCPHDCepheid lowered guidance could lead to upside potential, says Cowen
Cowen expects Cepheid to be under pressure today following the company's lowered guidance. The firm believes the guidance could position to the company to generated potential upside citing the establishment of confidence in execution, modest multiple expansion, and potential for upside to guidance. Shares are Outperform rated.
News For CPHD From The Last 14 Days
Check below for free stories on CPHD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:39 EDTCPHDCepheid sees Q2 revenue $113M-$115M, consensus $110.68M.
Subscribe for More Information
16:10 EDTCPHDCepheid sees FY14 non-GAAP EPS 19c-24c, may not compare with consensus (24c)
Sees FY14 revenue in the range of $446M-$461M. Sees FY14 net loss in a range from $(0.43) to $(0.38) per share. Expected non-GAAP net income excludes approximately $33M related to stock compensation expense, approximately $9M related to the amortization of debt discount and debt issuance costs, and approximately $3M related to the amortization of acquired intangibles.
16:07 EDTCPHDCepheid reports Q1 non-GAAP EPS (1c), may not compare with consensus (17c)
Subscribe for More Information
15:29 EDTCPHDNotable companies reporting after market close
Notable companies reporting before tomorrow's market open, with earnings consensus, include athenahealth (ATHN), consensus 17c; Allison Transmission (ALSN), consensus 31c; Investors Bancorp (ISBC), consensus 24c; Cepheid (CPHD), consensus (17c); Advanced Micro Devices (AMD), consensus 0c; Associated Banc-Corp (ASBC), consensus 25c; Hub Group (HUBG), consensus 36c; Capital Bank (CBF), consensus 24c; Select Comfort (SCSS), consensus 32c; Acacia Research (ACTG), consensus 4c.
April 10, 2014
07:03 EDTCPHDCepheid announces European release of Xpert Norovirus
Cepheid announced the release of Xpert Norovirus, a qualitative in vitro diagnostic test for rapid identification and differentiation of Noroviruses genogroup I and genogroup II, to be marketed as a CE IVD product under the European Directive on In Vitro Diagnostic Medical Devices. The test runs on Cepheid's GeneXpert System.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use